The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients
Background Anemia is frequently identified at the time of diagnosis in patients with diffuse large B‐cell lymphoma (DLBCL); however, studies addressing the prognostic significance of this important clinical parameter are lacking. Methods In this dual‐center study of patients with DLBCL (n = 556) tre...
Gespeichert in:
| Veröffentlicht in: | European journal of haematology 2015-12, Vol.95 (6), p.538-544 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 544 |
|---|---|
| container_issue | 6 |
| container_start_page | 538 |
| container_title | European journal of haematology |
| container_volume | 95 |
| creator | Troppan, Katharina T. Melchardt, Thomas Deutsch, Alexander Schlick, Konstantin Stojakovic, Tatjana Bullock, Marc D. Reitz, Daniel Beham-Schmid, Christine Weiss, Lukas Neureiter, Daniel Wenzl, Kerstin Greil, Richard Neumeister, Peter Egle, Alexander Pichler, Martin |
| description | Background
Anemia is frequently identified at the time of diagnosis in patients with diffuse large B‐cell lymphoma (DLBCL); however, studies addressing the prognostic significance of this important clinical parameter are lacking.
Methods
In this dual‐center study of patients with DLBCL (n = 556) treated with rituximab‐containing regimens, we evaluated the prognostic relevance of anemia at diagnosis in a training set (n = 211) and validated our findings in a second independent patient cohort (n = 345). Using Kaplan–Meier curves as well as univariate and multivariate Cox regression models, we analyzed the impact of anemia on 5‐year overall survival (OS) and 5‐year disease‐free survival (DFS) alongside established prognostic indicators including age, tumor stage, the revised International Prognostic Index (R‐IPI), and the recently published NCCN‐IPI. The influence of anemia on the predictive accuracy of IPI, R‐IPI, and NCCN‐IPI prognosis scores was subsequently determined using the Harrell's concordance index.
Results
Anemia was an independent predictor of impaired OS and DFS at 5 years in both DLBCL patient cohorts (P |
| doi_str_mv | 10.1111/ejh.12529 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1760926884</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1760926884</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4999-709e0caf2648ae8856353d6fcc01e50040a5cc742ed7bbe9ffabc6e0e934e0223</originalsourceid><addsrcrecordid>eNp1kctuGyEUhlHVqnEui75AxbJdTMIwF4buWit1HEVuFDnKEmHmYJPMrRxGrd8oj1lsJ9mVDYLznU9wfkI-pew8jesCHjfnKS-4fEcmaclYwkom35MJk4wneZ6nR-QY8ZExxmUqPpIjXpRCiIpPyPNyAxTdunPWGd0ZoL2lg4fgQYcWukB1B63T1HU0RBS83hF3yfx2Hks1XUyni_1h8P266zE4Q73DJ6oRAXGvCH3f4DeqaT3qJjHxCjzFMNbbnbZ21o4ItNF-DfRHrDcNbbbtsOlbTQcdXGzAU_LB6gbh7GU_Ifc_L5fTq-Tm12w-_X6TmFxKmQgmgRlteZlXGqqqKLMiq0trDEuhYCxnujBG5BxqsVqBtFavTAkMZJYD4zw7IV8O3vif3yNgUK3D3ZPiHPoRVSribHlZVXlEvx5Q43tED1YN3rXab1XK1C4YFYNR-2Ai-_lFO65aqN_I1yQicHEA_rgGtv83qcvrq1dlcuhwGODvW4f2T6oUmSjUw2Km7qrFdbWcCXWb_QOUYahq</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1760926884</pqid></control><display><type>article</type><title>The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients</title><source>MEDLINE</source><source>Wiley Journals</source><creator>Troppan, Katharina T. ; Melchardt, Thomas ; Deutsch, Alexander ; Schlick, Konstantin ; Stojakovic, Tatjana ; Bullock, Marc D. ; Reitz, Daniel ; Beham-Schmid, Christine ; Weiss, Lukas ; Neureiter, Daniel ; Wenzl, Kerstin ; Greil, Richard ; Neumeister, Peter ; Egle, Alexander ; Pichler, Martin</creator><creatorcontrib>Troppan, Katharina T. ; Melchardt, Thomas ; Deutsch, Alexander ; Schlick, Konstantin ; Stojakovic, Tatjana ; Bullock, Marc D. ; Reitz, Daniel ; Beham-Schmid, Christine ; Weiss, Lukas ; Neureiter, Daniel ; Wenzl, Kerstin ; Greil, Richard ; Neumeister, Peter ; Egle, Alexander ; Pichler, Martin</creatorcontrib><description>Background
Anemia is frequently identified at the time of diagnosis in patients with diffuse large B‐cell lymphoma (DLBCL); however, studies addressing the prognostic significance of this important clinical parameter are lacking.
Methods
In this dual‐center study of patients with DLBCL (n = 556) treated with rituximab‐containing regimens, we evaluated the prognostic relevance of anemia at diagnosis in a training set (n = 211) and validated our findings in a second independent patient cohort (n = 345). Using Kaplan–Meier curves as well as univariate and multivariate Cox regression models, we analyzed the impact of anemia on 5‐year overall survival (OS) and 5‐year disease‐free survival (DFS) alongside established prognostic indicators including age, tumor stage, the revised International Prognostic Index (R‐IPI), and the recently published NCCN‐IPI. The influence of anemia on the predictive accuracy of IPI, R‐IPI, and NCCN‐IPI prognosis scores was subsequently determined using the Harrell's concordance index.
Results
Anemia was an independent predictor of impaired OS and DFS at 5 years in both DLBCL patient cohorts (P < 0.001, log–rank test). In multivariate analysis, hemoglobin level was also a strong and independent prognostic indicator in patients stratified according to R‐IPI or NCCN‐IPI score. In survival analysis, the estimated concordance index, using IPI, R‐IPI, and NCCN‐IPI stratification measures (0.69, 0.64, and 0.70, respectively), improved to 0.70, 0.68, and 0.73, respectively, when anemia was also considered.
Conclusion
In this study, we have demonstrated that anemia at the time of diagnosis is an independent predictor of impaired clinical outcome in DLBCL. Furthermore, consideration of hemoglobin levels may improve the accuracy of recently established prognostic tools in lymphoma. Our data encourage further evaluation of the prognostic utility of this readily accessible biological parameter in prospective clinical trials.</description><identifier>ISSN: 0902-4441</identifier><identifier>EISSN: 1600-0609</identifier><identifier>DOI: 10.1111/ejh.12529</identifier><identifier>PMID: 25677782</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Anemia - diagnosis ; Anemia - drug therapy ; Anemia - etiology ; Anemia - mortality ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; diffuse large B-cell lymphoma ; Erythrocyte Indices ; Female ; hemoglobin ; Humans ; Kaplan-Meier Estimate ; Lymphoma, Large B-Cell, Diffuse - complications ; Lymphoma, Large B-Cell, Diffuse - drug therapy ; Lymphoma, Large B-Cell, Diffuse - mortality ; Male ; Middle Aged ; Patient Outcome Assessment ; Prognosis ; prognostic factors ; Proportional Hazards Models</subject><ispartof>European journal of haematology, 2015-12, Vol.95 (6), p.538-544</ispartof><rights>2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4999-709e0caf2648ae8856353d6fcc01e50040a5cc742ed7bbe9ffabc6e0e934e0223</citedby><cites>FETCH-LOGICAL-c4999-709e0caf2648ae8856353d6fcc01e50040a5cc742ed7bbe9ffabc6e0e934e0223</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fejh.12529$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fejh.12529$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25677782$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Troppan, Katharina T.</creatorcontrib><creatorcontrib>Melchardt, Thomas</creatorcontrib><creatorcontrib>Deutsch, Alexander</creatorcontrib><creatorcontrib>Schlick, Konstantin</creatorcontrib><creatorcontrib>Stojakovic, Tatjana</creatorcontrib><creatorcontrib>Bullock, Marc D.</creatorcontrib><creatorcontrib>Reitz, Daniel</creatorcontrib><creatorcontrib>Beham-Schmid, Christine</creatorcontrib><creatorcontrib>Weiss, Lukas</creatorcontrib><creatorcontrib>Neureiter, Daniel</creatorcontrib><creatorcontrib>Wenzl, Kerstin</creatorcontrib><creatorcontrib>Greil, Richard</creatorcontrib><creatorcontrib>Neumeister, Peter</creatorcontrib><creatorcontrib>Egle, Alexander</creatorcontrib><creatorcontrib>Pichler, Martin</creatorcontrib><title>The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients</title><title>European journal of haematology</title><addtitle>Eur J Haematol</addtitle><description>Background
Anemia is frequently identified at the time of diagnosis in patients with diffuse large B‐cell lymphoma (DLBCL); however, studies addressing the prognostic significance of this important clinical parameter are lacking.
Methods
In this dual‐center study of patients with DLBCL (n = 556) treated with rituximab‐containing regimens, we evaluated the prognostic relevance of anemia at diagnosis in a training set (n = 211) and validated our findings in a second independent patient cohort (n = 345). Using Kaplan–Meier curves as well as univariate and multivariate Cox regression models, we analyzed the impact of anemia on 5‐year overall survival (OS) and 5‐year disease‐free survival (DFS) alongside established prognostic indicators including age, tumor stage, the revised International Prognostic Index (R‐IPI), and the recently published NCCN‐IPI. The influence of anemia on the predictive accuracy of IPI, R‐IPI, and NCCN‐IPI prognosis scores was subsequently determined using the Harrell's concordance index.
Results
Anemia was an independent predictor of impaired OS and DFS at 5 years in both DLBCL patient cohorts (P < 0.001, log–rank test). In multivariate analysis, hemoglobin level was also a strong and independent prognostic indicator in patients stratified according to R‐IPI or NCCN‐IPI score. In survival analysis, the estimated concordance index, using IPI, R‐IPI, and NCCN‐IPI stratification measures (0.69, 0.64, and 0.70, respectively), improved to 0.70, 0.68, and 0.73, respectively, when anemia was also considered.
Conclusion
In this study, we have demonstrated that anemia at the time of diagnosis is an independent predictor of impaired clinical outcome in DLBCL. Furthermore, consideration of hemoglobin levels may improve the accuracy of recently established prognostic tools in lymphoma. Our data encourage further evaluation of the prognostic utility of this readily accessible biological parameter in prospective clinical trials.</description><subject>Adult</subject><subject>Aged</subject><subject>Anemia - diagnosis</subject><subject>Anemia - drug therapy</subject><subject>Anemia - etiology</subject><subject>Anemia - mortality</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>diffuse large B-cell lymphoma</subject><subject>Erythrocyte Indices</subject><subject>Female</subject><subject>hemoglobin</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Lymphoma, Large B-Cell, Diffuse - complications</subject><subject>Lymphoma, Large B-Cell, Diffuse - drug therapy</subject><subject>Lymphoma, Large B-Cell, Diffuse - mortality</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Patient Outcome Assessment</subject><subject>Prognosis</subject><subject>prognostic factors</subject><subject>Proportional Hazards Models</subject><issn>0902-4441</issn><issn>1600-0609</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctuGyEUhlHVqnEui75AxbJdTMIwF4buWit1HEVuFDnKEmHmYJPMrRxGrd8oj1lsJ9mVDYLznU9wfkI-pew8jesCHjfnKS-4fEcmaclYwkom35MJk4wneZ6nR-QY8ZExxmUqPpIjXpRCiIpPyPNyAxTdunPWGd0ZoL2lg4fgQYcWukB1B63T1HU0RBS83hF3yfx2Hks1XUyni_1h8P266zE4Q73DJ6oRAXGvCH3f4DeqaT3qJjHxCjzFMNbbnbZ21o4ItNF-DfRHrDcNbbbtsOlbTQcdXGzAU_LB6gbh7GU_Ifc_L5fTq-Tm12w-_X6TmFxKmQgmgRlteZlXGqqqKLMiq0trDEuhYCxnujBG5BxqsVqBtFavTAkMZJYD4zw7IV8O3vif3yNgUK3D3ZPiHPoRVSribHlZVXlEvx5Q43tED1YN3rXab1XK1C4YFYNR-2Ai-_lFO65aqN_I1yQicHEA_rgGtv83qcvrq1dlcuhwGODvW4f2T6oUmSjUw2Km7qrFdbWcCXWb_QOUYahq</recordid><startdate>201512</startdate><enddate>201512</enddate><creator>Troppan, Katharina T.</creator><creator>Melchardt, Thomas</creator><creator>Deutsch, Alexander</creator><creator>Schlick, Konstantin</creator><creator>Stojakovic, Tatjana</creator><creator>Bullock, Marc D.</creator><creator>Reitz, Daniel</creator><creator>Beham-Schmid, Christine</creator><creator>Weiss, Lukas</creator><creator>Neureiter, Daniel</creator><creator>Wenzl, Kerstin</creator><creator>Greil, Richard</creator><creator>Neumeister, Peter</creator><creator>Egle, Alexander</creator><creator>Pichler, Martin</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201512</creationdate><title>The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients</title><author>Troppan, Katharina T. ; Melchardt, Thomas ; Deutsch, Alexander ; Schlick, Konstantin ; Stojakovic, Tatjana ; Bullock, Marc D. ; Reitz, Daniel ; Beham-Schmid, Christine ; Weiss, Lukas ; Neureiter, Daniel ; Wenzl, Kerstin ; Greil, Richard ; Neumeister, Peter ; Egle, Alexander ; Pichler, Martin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4999-709e0caf2648ae8856353d6fcc01e50040a5cc742ed7bbe9ffabc6e0e934e0223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anemia - diagnosis</topic><topic>Anemia - drug therapy</topic><topic>Anemia - etiology</topic><topic>Anemia - mortality</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>diffuse large B-cell lymphoma</topic><topic>Erythrocyte Indices</topic><topic>Female</topic><topic>hemoglobin</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Lymphoma, Large B-Cell, Diffuse - complications</topic><topic>Lymphoma, Large B-Cell, Diffuse - drug therapy</topic><topic>Lymphoma, Large B-Cell, Diffuse - mortality</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Patient Outcome Assessment</topic><topic>Prognosis</topic><topic>prognostic factors</topic><topic>Proportional Hazards Models</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Troppan, Katharina T.</creatorcontrib><creatorcontrib>Melchardt, Thomas</creatorcontrib><creatorcontrib>Deutsch, Alexander</creatorcontrib><creatorcontrib>Schlick, Konstantin</creatorcontrib><creatorcontrib>Stojakovic, Tatjana</creatorcontrib><creatorcontrib>Bullock, Marc D.</creatorcontrib><creatorcontrib>Reitz, Daniel</creatorcontrib><creatorcontrib>Beham-Schmid, Christine</creatorcontrib><creatorcontrib>Weiss, Lukas</creatorcontrib><creatorcontrib>Neureiter, Daniel</creatorcontrib><creatorcontrib>Wenzl, Kerstin</creatorcontrib><creatorcontrib>Greil, Richard</creatorcontrib><creatorcontrib>Neumeister, Peter</creatorcontrib><creatorcontrib>Egle, Alexander</creatorcontrib><creatorcontrib>Pichler, Martin</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Troppan, Katharina T.</au><au>Melchardt, Thomas</au><au>Deutsch, Alexander</au><au>Schlick, Konstantin</au><au>Stojakovic, Tatjana</au><au>Bullock, Marc D.</au><au>Reitz, Daniel</au><au>Beham-Schmid, Christine</au><au>Weiss, Lukas</au><au>Neureiter, Daniel</au><au>Wenzl, Kerstin</au><au>Greil, Richard</au><au>Neumeister, Peter</au><au>Egle, Alexander</au><au>Pichler, Martin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients</atitle><jtitle>European journal of haematology</jtitle><addtitle>Eur J Haematol</addtitle><date>2015-12</date><risdate>2015</risdate><volume>95</volume><issue>6</issue><spage>538</spage><epage>544</epage><pages>538-544</pages><issn>0902-4441</issn><eissn>1600-0609</eissn><abstract>Background
Anemia is frequently identified at the time of diagnosis in patients with diffuse large B‐cell lymphoma (DLBCL); however, studies addressing the prognostic significance of this important clinical parameter are lacking.
Methods
In this dual‐center study of patients with DLBCL (n = 556) treated with rituximab‐containing regimens, we evaluated the prognostic relevance of anemia at diagnosis in a training set (n = 211) and validated our findings in a second independent patient cohort (n = 345). Using Kaplan–Meier curves as well as univariate and multivariate Cox regression models, we analyzed the impact of anemia on 5‐year overall survival (OS) and 5‐year disease‐free survival (DFS) alongside established prognostic indicators including age, tumor stage, the revised International Prognostic Index (R‐IPI), and the recently published NCCN‐IPI. The influence of anemia on the predictive accuracy of IPI, R‐IPI, and NCCN‐IPI prognosis scores was subsequently determined using the Harrell's concordance index.
Results
Anemia was an independent predictor of impaired OS and DFS at 5 years in both DLBCL patient cohorts (P < 0.001, log–rank test). In multivariate analysis, hemoglobin level was also a strong and independent prognostic indicator in patients stratified according to R‐IPI or NCCN‐IPI score. In survival analysis, the estimated concordance index, using IPI, R‐IPI, and NCCN‐IPI stratification measures (0.69, 0.64, and 0.70, respectively), improved to 0.70, 0.68, and 0.73, respectively, when anemia was also considered.
Conclusion
In this study, we have demonstrated that anemia at the time of diagnosis is an independent predictor of impaired clinical outcome in DLBCL. Furthermore, consideration of hemoglobin levels may improve the accuracy of recently established prognostic tools in lymphoma. Our data encourage further evaluation of the prognostic utility of this readily accessible biological parameter in prospective clinical trials.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>25677782</pmid><doi>10.1111/ejh.12529</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0902-4441 |
| ispartof | European journal of haematology, 2015-12, Vol.95 (6), p.538-544 |
| issn | 0902-4441 1600-0609 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1760926884 |
| source | MEDLINE; Wiley Journals |
| subjects | Adult Aged Anemia - diagnosis Anemia - drug therapy Anemia - etiology Anemia - mortality Antineoplastic Combined Chemotherapy Protocols - therapeutic use diffuse large B-cell lymphoma Erythrocyte Indices Female hemoglobin Humans Kaplan-Meier Estimate Lymphoma, Large B-Cell, Diffuse - complications Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - mortality Male Middle Aged Patient Outcome Assessment Prognosis prognostic factors Proportional Hazards Models |
| title | The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T01%3A21%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20significance%20of%20pretreatment%20anemia%20in%20the%20era%20of%20R-IPI%20and%20NCCN-IPI%20prognostic%20risk%20assessment%20tools:%20a%20dual-center%20study%20in%20diffuse%20large%20B-cell%20lymphoma%20patients&rft.jtitle=European%20journal%20of%20haematology&rft.au=Troppan,%20Katharina%20T.&rft.date=2015-12&rft.volume=95&rft.issue=6&rft.spage=538&rft.epage=544&rft.pages=538-544&rft.issn=0902-4441&rft.eissn=1600-0609&rft_id=info:doi/10.1111/ejh.12529&rft_dat=%3Cproquest_cross%3E1760926884%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1760926884&rft_id=info:pmid/25677782&rfr_iscdi=true |